Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

Quest Diagnostics

Other names: Blueprint Genetics | Celera Genomics | Axys Pharma | Quest Diagnostics | Quest Diagnostics Incorporated | Celera Genomics Corporation | Celera Corporation | Axys Pharmaceuticals | Axys Pharmaceuticals, Inc | Axys Pharmaceuticals, Inc.
Related tests:


Quest Diagnostics completes acquisition of Northern Light Laboratory in Maine (Quest Diagnostics Press Release)
"Quest Diagnostics...announced it has completed its previously announced acquisition of select assets of Northern Light Laboratory...Quest now provides professional laboratory management services for nine of Northern Light Health's hospital laboratories, along with its cancer center laboratory at Northern Light Cancer Care in Brewer, Maine."
Cleveland Diagnostics Announces Agreement with Quest Diagnostics to Expand Patient Access to IsoPSA Prostate Cancer Testing (Businesswire)
"Cleveland Diagnostics, Inc...announced an agreement designed to expand patient access to Cleveland Diagnostics’ novel prostate cancer test, IsoPSA. Through an agreement with Quest Diagnostics...the nation’s leading provider of diagnostic information services, patients will be able to access IsoPSA and, once ordered by their physician, provide a blood specimen for testing at one of over 2,100 Quest Diagnostics patient service center locations nationwide later this year. With its national logistics network, Quest will transport the specimens to Cleveland Diagnostics’ laboratory for testing. The parties expect physicians will be able to begin offering the test to patients through Quest Diagnostics in the second quarter of 2023."
Licensing / partnership
Agilent to Collaborate with Quest Diagnostics to Extend Access to the Agilent Resolution ctDx FIRST Liquid Biopsy Test (Agilent Technologies Press Release)
"Agilent Technologies Inc....announced an agreement with Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services. The alliance will enable providers and patients throughout the United States to access the Agilent Resolution ctDx FIRST liquid biopsy next-generation sequencing (NGS) test....The agreement between Quest and Agilent will enable broad adoption for ctDx FIRST, a single-site premarket approved (ssPMA) test performed at the Resolution Bioscience CLIA laboratory in Kirkland, Washington....Under the terms of the agreement, Quest will offer ctDx FIRST to healthcare providers in the United States seeking a minimally invasive liquid biopsy test option as a CDx for KRAZATI."
Licensing / partnership
Agilent Resolution ctDx FIRST Assay
Krazati (adagrasib)
Quest Diagnostics and Northern Light Health form strategic laboratory collaboration to improve access to affordable diagnostic services in Maine (Quest Diagnostics Press Release)
"Quest Diagnostics...and Northern Light Health...announced a strategic laboratory collaboration designed to broaden access to innovative, quality and cost-effective laboratory services powering affordable care for communities in Maine...Quest will also provide professional laboratory management services for nine of Northern Light Health's hospital laboratories, along with its cancer center laboratory at Northern Light Cancer Care in Brewer, Maine."
Licensing / partnership
Quest Diagnostics now offers Biocept’s liquid biopsy test for lung cancer, expanding its menu of advanced cancer diagnostics (Quest Diagnostics Press Release)
"Physicians in the United States can now order the liquid biopsy-based Target Selector™ NGS Lung Panel test directly from Quest Diagnostics...Developed by Biocept, Inc...the lab-developed liquid biopsy test aids genomic profiling in patients with advanced non-small cell lung cancer (NSCLC), helping physicians identify potential targeted therapies and monitor the effectiveness of treatment...The Target Selector NGS Lung Panel contributes to better patient outcomes by providing physicians with direction on therapeutic options for those battling NSCLC."
Licensing / partnership
Target Selector™ NGS Lung Panel
Quest Diagnostics to Introduce Ki-67 IHC MIB-1 pharmDx, the First Companion Diagnostic for Eli Lilly and Company’s Verzenio (abemaciclib), a CDK4/6 Inhibitor for Certain People with HR+ HER2- High Risk Early Breast Cancer (Quest Diagnostics Press Release)
"Quest Diagnostics...announced that it will provide clinical laboratory testing using the Ki-67 IHC MIB-1 pharmDx (Dako Omnis) immunohistochemistry companion diagnostic...In aligned actions, the FDA also granted pre-market approval to Ki-67 IHC MIB-1 pharmDx (Dako Omnis) from Agilent Technologies, Inc. as a companion diagnostic for Verzenio. Quest is the first laboratory to have validated the test in conjunction with Agilent. Since the validation of an IVD assay can take weeks, Quest is committed to providing the test as soon as possible, with plans to make it nationally available by the end of the month."
Ki-67 IHC MIB-1 pharmDx
Verzenio (abemaciclib)
Quest Diagnostics and Select Health of South Carolina enter agreement to expand laboratory network for First Choice members (Quest Diagnostics Press Release)
"Select Health of South Carolina and Quest Diagnostics announced they have entered into an agreement that expands Select Health’s laboratory network for its Medicaid and Medicare-Medicaid dual eligible enrollees...Select Health...offers the First Choice Medicaid health plan statewide and the First Choice VIP Care Plus Medicare-Medicaid plan (MMP) in 42 counties. Members of both health plans are now able to obtain in-network laboratory services from Quest’s 20 locations throughout the state."
Medicare • Licensing / partnership
Biocept to collaborate with Quest Diagnostics to provide advanced NGS-based liquid biopsy testing for patients with lung cancer (Biocept Press Release)
"Biocept, Inc...today announced a collaboration with Quest Diagnostics...to provide laboratory testing services to Quest patients for its Target Selector™ NGS-based liquid biopsy targeted lung cancer panel. Quest Diagnostics is the leading provider of diagnostic information services, including in advanced diagnostics...The two parties expect the service to be available to Quest Diagnostics’ providers and patients in the fourth quarter of 2021."
Licensing / partnership
Epizyme Launches EZH2Now Testing Program with Quest Diagnostics for Relapsed or Refractory Follicular Lymphoma Patients (Epizyme Press Release)
"Epizyme…today launched the EZH2Now Testing Program, an Epizyme initiative in collaboration with Quest Diagnostics…to provide EZH2 mutation testing for patients with relapsed or refractory (R/R) follicular lymphoma (FL)…‘Our participation in the EZH2Now Testing Program not only delivers on this goal, but also highlights Quest Diagnostics’ commitment to innovations in oncology and advanced diagnostics that improve patient care, as well as our deep specialization in hematopathology. Sponsored testing programs such as this one with Epizyme can be powerful mechanisms to arm physicians and patients with data to support treatment plans.'"
Licensing / partnership
Quest Diagnostics and Paige form collaboration to advance AI-generated pathology insights to improve cancer diagnosis and care (Quest Diagnostics Press Release)
"Quest Diagnostics...and Paige today announced a collaboration designed to unlock the potential of artificial intelligence (AI) to improve and speed the diagnosis of cancer and other diseases that rely on pathologic assessment. The collaboration involves analysis using Paige's proprietary machine learning expertise of pathology diagnostic data and digitized slides from Quest Diagnostics and its AmeriPath and Dermpath businesses to uncover markers of cancer and other diseases...The collaboration will initially focus on solid tumor cancers, such as prostate, breast, colorectal and lung. The agreement involves shared revenue for achieving certain product and commercial milestones and, assuming regulatory approval, arrangements for Quest to use approved software products in its pathology operations as well as joint marketing and research. In addition, Quest's pathologists will aid in defining pathology workflows for using the products to support diagnostic decision-making."
Licensing / partnership
GRAIL and Quest Diagnostics announce collaboration to support Galleri, first-of-kind multi-cancer early detection blood test (Grail Press Release)
"GRAIL, Inc...today announced an agreement with Quest Diagnostics...to provide phlebotomy services to support Galleri™, GRAIL’s multi-cancer early detection blood test...Quest’s phlebotomy network will help provide blood specimen collection for Galleri in the United States once the test becomes available this year...Galleri is available under investigational use in PATHFINDER, GRAIL’s prospective, interventional study evaluating the implementation of Galleri in clinical practice. Galleri is also expected to be offered to eligible patients in the United Kingdom (UK) later this year as part of a partnership with the UK National Health Service to support its Long Term Plan for earlier cancer diagnoses in an effort to transform cancer outcomes."
Licensing / partnership
Galleri Test
Quest Diagnostics launches automated next generation sequencing (NGS) engine to power AncestryHealth® (Quest Diagnostics)
“A new innovation in advanced genetic sequencing automation from Quest Diagnostics…will now enable individuals to access highly accurate genetic testing providing insights into inherited diseases including cancers of the breast, colon and other conditions through AncestryHealth®…Quest developed a faster and cheaper way to perform next generation sequencing (NGS) to power AncestryHealth, a new consumer genetics offering launched by Ancestry® on August 3….Quest is providing the technology for use in AncestryHealth and AncestryDNA® offerings under an exclusive agreement."